Literature DB >> 9509259

Human ehrlichioses: newly recognized infections transmitted by ticks.

J S Dumler1, J S Bakken.   

Abstract

Human ehrlichioses are tick-borne infections caused by bacteria in the genus Ehrlichia. Human monocytic ehrlichiosis is caused by Ehrlichia chaffeensis and human granulocytic ehrlichiosis is caused by an agent similar to Ehrlichia equi. E. chaffeensis infects mononuclear phagocytes and is transmitted by Lone Star ticks (Amblyomma americanum) found in the south central and eastern United States. The agent of human granulocytic ehrlichiosis infects mostly neutrophils, it transmitted by Ixodes species ticks, and occurs mostly in the upper midwest and northeast United States. Despite the undifferentiated presentation of both ehrlichioses with fever, headache, myalgias, leukopenia, thrombocytopenia, and elevated liver enzyme activities, the diagnostic methods are distinct. Occasional severe complications include meningoencephalitis, adult respiratory distress syndrome, shock, and opportunistic infections. Immunocompromised patients are at high risk for death. An adverse outcome is associated with delayed diagnosis and therapy; thus, empirical treatment is advocated. Treatment with doxycycline usually results in prompt defervescence and cure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9509259     DOI: 10.1146/annurev.med.49.1.201

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  54 in total

Review 1.  Response of the clinical microbiology laboratory to emerging (new) and reemerging infectious diseases.

Authors:  Franklin R Cockerill; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

2.  Molecular differentiation of metastriate tick immatures.

Authors:  Jennifer M Anderson; Nicole C Ammerman; Douglas E Norris
Journal:  Vector Borne Zoonotic Dis       Date:  2004       Impact factor: 2.133

3.  Ehrlichia Meningitis Mimicking Aneurysmal Subarachnoid Hemorrhage: A Case Study for Medical Decision-Making Heuristics.

Authors:  Brynn Dredla; William D Freeman
Journal:  Neurohospitalist       Date:  2015-08-02

4.  Early transcriptional response of human neutrophils to Anaplasma phagocytophilum infection.

Authors:  Bindu Sukumaran; Jason A Carlyon; Ji-Lian Cai; Nancy Berliner; Erol Fikrig
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Two immunoregulatory peptides with antioxidant activity from tick salivary glands.

Authors:  Jing Wu; Yipeng Wang; Han Liu; Hailong Yang; Dongying Ma; Jianxu Li; Dongsheng Li; Ren Lai; Haining Yu
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 6.  Invasion of the central nervous system by intracellular bacteria.

Authors:  Douglas A Drevets; Pieter J M Leenen; Ronald A Greenfield
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Detection and identification of Ehrlichia spp. in ticks collected in Tunisia and Morocco.

Authors:  M'Hammed Sarih; Youmna M'Ghirbi; Ali Bouattour; Lise Gern; Guy Baranton; Danièle Postic
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Ehrlichia chaffeensis antibodies in white-tailed deer, Iowa, 1994 and 1996.

Authors:  L Mueller-Anneling; M J Gilchrist; P S Thorne
Journal:  Emerg Infect Dis       Date:  2000 Jul-Aug       Impact factor: 6.883

9.  In vivo and in vitro studies on Anaplasma phagocytophilum infection of the myeloid cells of a patient with chronic myelogenous leukaemia and human granulocytic ehrlichiosis.

Authors:  M Bayard-Mc Neeley; A Bansal; I Chowdhury; G Girao; C B Small; K Seiter; J Nelson; D Liveris; I Schwartz; D F Mc Neeley; G P Wormser; M E Aguero-Rosenfeld
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection.

Authors:  Jason A Carlyon; Dalia Abdel-Latif; Marc Pypaert; Paige Lacy; Erol Fikrig
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.